Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers

Table 4 The baseline of training and testing groups, n (%)

Characteristics	Training group (n = 402)	Testing group (n = 170)	P value
Etiology
AIH	44 (10.90)	16 (9.40)	0.572
Hepatitis	268 (66.70)	121 (71.20)
Others	90 (22.40)	33 (19.40)
Ascites
No	138 (34.30)	76 (44.70)	0.024
Yes	264 (65.70)	94 (55.30)
GOV
No	56 (13.90)	24 (14.10)	1.000
Yes	346 (86.1)	146 (85.90)
PLT
< 85	287 (71.40)	129 (75.90)	0.318
≥ 85	115 (28.60)	41 (24.10)
D-D
≤ 2.52	262 (65.20)	99 (58.20)	0.140
>2.52	140 (34.80)	71 (41.80)
PVD
< 14.5	253 (62.90)	114 (67.10)	0.398
≥ 14.5	149 (37.10)	56 (32.90)
PVV
< 20.05	196 (48.80)	89 (52.40)	0.487
≥ 20.05	206 (51.20)	81 (47.60)
ANRI
< 48	344 (85.60)	141 (82.90)	0.501
≥ 48	58 (14.40)	29 (17.10)
PLR
≤ 68.06	148 (36.80)	58 (34.10)	0.604
> 68.06	254 (63.20)	112 (65.90)

AIH: Autoimmune hepatitis; GOV: Gastroesophageal varices; PLT: Platelet count; D-D: D-dimer; PVD: Portal vein diameter; PVV: Portal vein velocity; ANRI: Aspartate transaminase to neutrophil ratio index; PLR: Platelet-to-lymphocyte ratio.